Scarica l'app Stockscreener
25.62
1.50%
-0.39
Dopo l'orario di chiusura:
25.65
0.03
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics stock sits 35.28 percent below its high as Bo Cumbo joins board - AD HOC NEWS
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - Kalkine Media
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan
Stoke Therapeutics stock reports USD 9.33 million Q2 revenue - AD HOC NEWS
Ruth Walker Appointed Vice President, People & Culture at Stoke Therapeutics - hrtoday.in
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com India
[Form 3] Stoke Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan
Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Stoke Therapeutics, Inc. (STOK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, E - The National Law Review
Stoke Therapeutics appoints Bo Cumbo to board of directors By Investing.com - Investing.com Canada
STOK Looks 163.2% Overvalued on GF Value™ - GuruFocus
Stoke Therapeutics appoints Bo Cumbo to board of directors - Investing.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization - Business Wire
Stoke Therapeutics (NASDAQ:STOK) Shares Down 9%What's Next? - MarketBeat
Stoke Therapeutics Appoints Bo Cumbo to Its B - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
News - planetario.buenosaires.gob.ar
Stoke Therapeutics stock holds gains after recent data update - AD HOC NEWS
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Exploring a 60.60% Potential Upside in Biotechnology - DirectorsTalk Interviews
ETFs Investing in Stoke Therapeutics, Inc. Stocks - TradingView
Stoke (STOK) Breaks Out with +4.23% Surge Past $30.54 2026-09-17Zero Lag EMA - siam.in
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)September 16, 2026 - BioSpace
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics at Cantor conference: dravet data, cash runway - Investing.com
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - The Manila Times
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics grants inducement options to new CSO - scanx.trade
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):